See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Donald Trump
Trade War
Natural Disasters
Social Media
Trade
Baseball
Stock Markets
Senate
European Union
U.S.-Canada Relations
Published • loading... • Updated

Avidity is pursuing accelerated approval for del-zota in the U.S.

Summary by CureDuchenne
CureDuchenne was an early funder of Avidity, and today we share an important milestone: Enrollment is now complete for the EXPLORE44-OLE clinical trial. Avidity is pursuing accelerated approval for del-zota in the U.S., with plans to file a Biologics License Application (BLA) by the end of the year.Stay tuned—top-line data from the EXPLORE44® Phase 1/2 trial will be shared next month.Learn more: https://aviditybiosciences.investorroom.com/2025-0…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
CureDuchenneCureDuchenne

Avidity is pursuing accelerated approval for del-zota in the U.S.

CureDuchenne was an early funder of Avidity, and today we share an important milestone: Enrollment is now complete for the EXPLORE44-OLE clinical trial. Avidity is pursuing accelerated approval for del-zota in the U.S., with plans to file a Biologics License Application (BLA) by the end of the year.Stay tuned—top-line data from the EXPLORE44® Phase 1/2 trial will be shared next month.Learn more: https://aviditybiosciences.investorroom.com/2025-0…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

CureDuchenne broke the news in on Friday, February 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal